

# World Journal of *Clinical Oncology*

*World J Clin Oncol* 2017 April 10; 8(2): 96-177



## Contents

Bimonthly Volume 8 Number 2 April 10, 2017

### EDITORIAL

- 96 *Watch and wait* policy in advanced neuroendocrine tumors: What does it mean?  
*Fazio N*

- 100 Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate  
*Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T*

### FRONTIER

- 106 Leptin signaling and cancer chemoresistance: Perspectives  
*Candelaria PV, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR*

### REVIEW

- 120 Targeted therapies in breast cancer: New challenges to fight against resistance  
*Masoud V, Pagès G*

### MINIREVIEWS

- 135 How best to manage gastrointestinal stromal tumor  
*Lanke G, Lee JH*
- 145 Immunotherapies in sarcoma: Updates and future perspectives  
*Ghosn M, El Rassy E, Kourie HR*

### ORIGINAL ARTICLE

#### Retrospective Study

- 151 Bethesda System for Reporting Thyroid Cytopathology: A three-year study at a tertiary care referral center in Saudi Arabia  
*Al Dawish MA, Robert AA, Muna A, Eyad A, Al Ghamdi A, Al Hajeri K, Thabet MA, Braham R*

#### Clinical Trials Study

- 158 Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients  
*Guo N, Wang WQ, Gong XJ, Gao L, Yang LR, Yu WN, Shen HY, Wan LQ, Jia XF, Wang YS, Zhao Y*

#### Observational Study

- 168 Gastric and duodenal polyps in familial adenomatous polyposis patients: Conventional endoscopy *vs* virtual chromoendoscopy (fujinon intelligent color enhancement) in dysplasia evaluation  
*Lami G, Galli A, Macrì G, Dabizzi E, Biagini MR, Tarocchi M, Messerini L, Valanzano R, Milani S, Polvani S*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Oncology*, Hua-Feng Wei, MD, PhD, Research Associate, Cancer Center Lab, General Hospital of Chinese PLA, China and Second Military Medical University, International Joint Cancer Institute, Beijing 100853, China

**AIM AND SCOPE**

*World Journal of Clinical Oncology (World J Clin Oncol, WJCO*, online ISSN 2218-4333, DOI: 10.5306) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJCO* covers a variety of clinical medical topics, including etiology, epidemiology, evidence-based medicine, informatics, diagnostic imaging, endoscopy, tumor recurrence and metastasis, tumor stem cells, radiotherapy, chemotherapy, interventional radiology, palliative therapy, clinical chemotherapy, biological therapy, minimally invasive therapy, physiotherapy, psycho-oncology, comprehensive therapy, and oncology-related nursing. Priority publication will be given to articles concerning diagnosis and treatment of oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJCO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

**INDEXING/ABSTRACTING**

*World Journal of Clinical Oncology* is now indexed in PubMed, PubMed Central and Scopus.

**FLYLEAF**

**I-III** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Ya-Jing Lu*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Fang-Fang Ji*  
**Proofing Editorial Office Director:** *Xiu-Xia Song*

**NAME OF JOURNAL**  
*World Journal of Clinical Oncology*

**ISSN**  
 ISSN 2218-4333 (online)

**LAUNCH DATE**  
 November 10, 2010

**FREQUENCY**  
 Bimonthly

**EDITOR-IN-CHIEF**  
**Godefridus J Peters, PhD, Professor**, Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam 1081 HV, Netherlands

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/2218-4333/editorialboard.htm>

**EDITORIAL OFFICE**  
 Xiu-Xia Song, Director

*World Journal of Clinical Oncology*  
 Baishideng Publishing Group Inc  
 8226 Regency Drive, Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 8226 Regency Drive, Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 April 10, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
<http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.f6publishing.com>

## Observational Study

**Gastric and duodenal polyps in familial adenomatous polyposis patients: Conventional endoscopy vs virtual chromoendoscopy (fujinon intelligent color enhancement) in dysplasia evaluation**

Gabriele Lami, Andrea Galli, Giuseppe Macrì, Emanuele Dabizzi, Maria Rosa Biagini, Mirko Tarocchi, Luca Messerini, Rosa Valanzano, Stefano Milani, Simone Polvani

Gabriele Lami, Andrea Galli, Maria Rosa Biagini, Mirko Tarocchi, Stefano Milani, Simone Polvani, Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy

Andrea Galli, Giuseppe Macrì, Maria Rosa Biagini, Mirko Tarocchi, Stefano Milani, Clinical Gastroenterology Unit, Careggi University Hospital, 50134 Florence, Italy

Emanuele Dabizzi, Gastroenterology and Gastrointestinal Endoscopy, San Raffaele Hospital, 20132 Milan, Italy

Luca Messerini, Division of Pathological Anatomy, Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy

Rosa Valanzano, Surgical Unit, Department of Translational Surgery and Medicine, University of Florence, 50139 Florence, Italy

**Author contributions:** Lami G, Macrì G, Galli A and Dabizzi E contributed to the study conception, design and supervision; Lami G, Galli A, Macrì G, Dabizzi E and Valenzano R performed the patients recruitment and samples collection; Messerini L supervised the histological examination; Lami G and Biagini MR collected the data and performed the statistical analysis; Milani S reviewed the statistical methods; Lami G, Galli A, Macrì G, Milani S, Dabizzi E, Biagini MR, Messerini L and Polvani S contributed to the interpretation of the data and discussion of the results; Tarocchi M critically revised the manuscript; Lami G, Galli A and Polvani S drafted the manuscript.

**Institutional review board statement:** The study was reviewed and approved by the AOU Careggi Institutional Review Board.

**Informed consent statement:** All study participant, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors have nothing to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Simone Polvani, PhD, Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, viale Pieraccini 6, 50139 Florence, Italy. [simone.polvani@unifi.it](mailto:simone.polvani@unifi.it)  
Telephone: +39-055-2758115

**Received:** August 26, 2016

**Peer-review started:** August 27, 2016

**First decision:** November 19, 2016

**Revised:** February 22, 2017

**Accepted:** February 25, 2017

**Article in press:** February 26, 2017

**Published online:** April 10, 2017

**Abstract****AIM**

To test the fujinon intelligent color enhancement (FICE) in identifying dysplastic or adenomatous polyps in familial adenomatous polyposis (FAP) patients.

**METHODS**

Seventy-six consecutive FAP patients, already treated by colectomy and members of sixty-five families, were enrolled. A FICE system for the upper gastro-intestinal tract with an electronic endoscope system and a standard duodenoscope (for side-viewing examination) were used by two expert examiners. Endoscopic resection was performed with diathermic loop for polyps  $\geq$  6 mm and with forceps for polyps  $<$  6 mm. Formalin-fixed biopsy specimens were analyzed by two expert gastrointestinal pathologists blinded to size, location and number of FAP-associated fundic gland polyps.

**RESULTS**

Sixty-nine (90.8%) patients had gastric polyps (34 only in the corpus-fundus, 7 only in the antrum and 28 in the whole stomach) and 52 (68.4%) in duodenum (7 in the bulb, 35 in second/third duodenal portion, 10 both in the bulb and the second portion of duodenum). In the stomach fundus after FICE evaluation, 10 more polyps were removed from 10 patients for suspicious features of dysplasia or adenomas, but they were classified as cystic fundic gland after histology. In the antrum FICE identified more polyps than traditional endoscopy, showing a better tendency to identify adenomas and displastic areas. In the duodenum FICE added a significant advantage in identifying adenomas in the bulb and identified more polyps in the II/III portion.

**CONCLUSION**

FICE significantly increases adenoma detection rate in FAP patients but does not change any Spigelman stage and thus does not modify patient's prognosis and treatment strategies.

**Key words:** Fujinon intelligent color enhancement; Familial adenomatous polyposis; Spigelman; Endoscopy; Polyp; Adenoma; Stomach; Duodenum

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Colon endoscopic surveillance and prophylactic colectomy have strongly reduced mortality due to colorectal carcinoma and have improved survival of familial adenomatous polyposis (FAP) patients, leading to the development of surveillance for extra-colonic cancers. Polyps in the duodenum and stomach are frequent findings in FAP. The timing of endoscopic and histology surveillance is currently a great challenge. Spectral estimation by fujinon intelligent color enhancement (FICE) may identify dysplasia and discriminate between adenomatous and non-adenomatous polyps. Interestingly, application of FICE to FAP patients significantly increases the detection of adenomas but does not yet change the prognosis, surveillance program and treatment strategies.

Lami G, Galli A, Macri G, Dabizzi E, Biagini MR, Tarocchi M, Messerini L, Valanzano R, Milani S, Polvani S. Gastric and duodenal polyps in familial adenomatous polyposis patients:

Conventional endoscopy vs virtual chromoendoscopy (fujinon intelligent color enhancement) in dysplasia evaluation. *World J Clin Oncol* 2017; 8(2): 168-177 Available from: URL: <http://www.wjgnet.com/2218-4333/full/v8/i2/168.htm> DOI: <http://dx.doi.org/10.5306/wjco.v8.i2.168>

**INTRODUCTION**

Familial adenomatous polyposis (FAP) is an autosomal dominant inherited syndrome characterized by the development of colorectal cancer by the age of 40 years in nearly 100% of individuals<sup>[1]</sup>. Colon Endoscopic surveillance and prophylactic colectomy have strongly reduced mortality due to colorectal carcinoma and have improved survival of FAP patients with minimal consequences<sup>[2,3]</sup>, leading to the introduction of surveillance strategies for the prevention of other extra-colonic malignancies<sup>[4]</sup>.

The duodenum is the second most common site of polyps development after colon, with a life-time risk of duodenal adenomas that approaches 100% in FAP affected individuals<sup>[5,6]</sup>. The cumulative risk of duodenal cancer or high grade of dysplasia by the age of 60 years is 4%-10%<sup>[6-8]</sup>.

Endoscopic surveillance and removal of neoplastic tissue is useful in the prevention of duodenal cancer<sup>[8]</sup>. However, the choice of treatment and the optimal timing of surveillance based on endoscopic and histopathology examination for each patient is currently a great challenge. Currently the surveillance of duodenum is based on the Spigelman classification of duodenal adenomatosis (Table 1); however, this staging system has low predictive values and has never been validated<sup>[6,8]</sup>.

Gastric polyps are also a common finding in patients with FAP: they mostly consist of FAP-associated fundic gland polyps (FGPs) reported to occur at variable rates, up to 88%<sup>[9,10]</sup>, against a strongly smaller rate (0.8%-5.0%)<sup>[11,12]</sup> in non-FAP subjects who undergo an esophagogastroduodenoscopy (EGD).

FGPs have historically been considered non-neoplastic lesions without malignant potential<sup>[13]</sup>; however recent studies have questioned this assumption reporting high rates of low and high grade dysplasia (up to 54%)<sup>[9,14,15]</sup>. In particular, European and Asian registries of FAP patients proved the presence of gastric carcinoma arising from FGPs in FAP patients and an incidence of gastric adenocarcinoma between 0.6% and 4.0%<sup>[16-19]</sup>.

Other common types of gastric polyps are represented by adenomas (gastric foveolar or intestinal type-gastric adenomas and pyloric gland adenomas) which are reported in approximately 10% of gastric polyps in FAP patients<sup>[10,20,21]</sup> and which can arise in the gastric antrum, in the gastric body-fundus or in the context of FGP<sup>[22]</sup>. So, identification of dysplastic lesions or adenomatous tissue in these patients is often made difficult by the great number of polyps (up to hundreds) and by the patchy

**Table 1** Demographic features

Features	Patients
Total	76
Age (yr)	Mean 40.3 (24-64)
Gender	
Male	41 (53.9%)
Female	35 (46.1%)
Prior surgery	
IRA	10 (13.2%)
IPAA	66 (86.8%)
Chemoprevention	16 (21.1%)
NSAIDS intake	17 (22.4%)
Tobacco exposure	21 (27.6%)
PPI/anti-H2 intake	14 (18.4%)
Family history of GI malignancies	
None	31 (40.8%)
1 member	32 (42.1%)
2 members	10 (13.2%)
3 members	3 (3.9%)
Spigelman duodenal stage	
0	28 (36.8%)
I	7 (9.2%)
II	34 (44.8%)
III	7 (9.2%)
IV	0 (0.0%)

IRA: Total colectomy and ileo-rectal anastomosis; IPAA: Total proctocolectomy and ileopouch-anal anastomosis; NSAIDS: Non steroidal anti-inflammatory drugs; PPI: Proton pump inhibitors.

distribution of dysplasia.

By now, dysplasia finding in this subgroup of subjects is made on the basis of random biopsies<sup>[9]</sup> which lead to a time consuming, laborious and poorly performing procedure, that can result in a high rate of missed lesions. According to that, it would be useful identifying FGPs at risk of malignant degeneration.

A better characterization of patients, an optimized program of surveillance and a good survival are possible with a selective and complete asportation and with a careful histological evaluation.

It is well known that is possible to predict the histology of a mucosal lesion by observing the crypt orifices (the so called pit pattern) of mucosal glands<sup>[23]</sup> and the capillary pattern of the mucosa<sup>[24]</sup>. Several endoscopic imaging techniques have been proposed to enhance the details of these patterns<sup>[25]</sup>. Among these, chromoendoscopy is a widely applied staining method that uses biocompatible dye agents which accumulate within crypt orifices during endoscopy<sup>[26]</sup>. Although chromoendoscopy is effective for many applications, it still has some problems, such as difficulty in achieving complete and even coating of the mucosal surface with the dye, the extra cost of the equipment needed for dye spraying and the extra time required to perform the procedure. Moreover, traditional chromoendoscopy isn't able to enhance the capillary pattern, whose evaluation is essential in early diagnoses of malignant lesions<sup>[24]</sup>. In attempt to resolve these problems, other endoscopic technologies have been developed. Fujinon intelligent color enhancement (FICE™, Fujinon Corp, Saitama, Japan) represents a spectral estimation technique based on arithmetically processing of a white-

light image captured by a video endoscope and sent to the spectral-estimation matrix-processing circuit. The image of the white-light endoscopic observation is resolved in each color image of the red, green and blue signal. Next, each resolved image is converted into various presumed wavelength images by a pixel unit. The images of an arbitrary single wavelength are then extracted and reconstructed. Due to its variable setting functions (up to 10) it is possible to select flexibly the most suitable wavelengths required for examination. Preliminary studies suggested that FICE successfully achieved enhancements of real-time observations of mucosal and microvascular patterns<sup>[27,28]</sup>.

The light penetration into the mucosa varies according to the wavelengths: Those in the 400-500 nm range are ideal for analyzing surface structures whereas, because of the absorption properties of hemoglobin, longer wavelengths of about 550 nm are more effective for the visualization of blood vessels.

FICE seems able to discriminate between adenomatous and non-adenomatous polyps and to identify the presence of dysplasia<sup>[29-32]</sup>. Few studies have been conducted to determine the efficacy of chromoendoscopy, both traditional and virtual, in the evaluation of duodenal and peri-ampullary adenomatous polyps in FAP patients<sup>[33-35]</sup>. Interestingly, FICE application in the discrimination between neoplastic and non-neoplastic gastric lesions has not been thoroughly investigated<sup>[36-39]</sup>, and no data are available about FICE in evaluating FGPs dysplasia or application of FICE for the screening of FAP patients.

In FAP cohort, the specific identification of who is at a greater risk of cancer development could be of paramount importance to assure a personalized program of surveillance or a therapeutic intervention.

The primary aim of this study was to assess the capability of FICE in identifying gastric polyps with dysplastic or adenomatous tissue in comparison to traditional endoscopy and in identifying a greater number of duodenal adenomas with advanced histological features.

Secondary aim was to assess the capability of FICE in identifying adenomas not seen on white light evaluation.

## MATERIALS AND METHODS

### Patients

Seventy-six consecutive FAP patients, already treated by colectomy and members of sixty-five families, were enrolled. Exclusion criteria were: Uncorrectable coagulopathy, inability to give informed consent, age < 18 years, prior gastro-duodenal surgery or a personal history of gastro-duodenal cancer. All patients underwent a surveillance esophagogastroduodenoscopy (EGD) in deep sedation at the Gastroenterology U.O. of the Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy. Written informed consent were obtained before EGD and sedation.

### Endoscopy

A FICE system (EG-590ZW; Fujinon Corp, Saitama,

Japan) for the upper gastro-intestinal tract with an electronic endoscope system (EPX-4400; Fujinon Corp, Saitama, Japan) was used for this study. In this system, ten channels with different predefined combinations of absorption wavelengths are available. We used channel 5, corresponding to R 500 nm, G 480 nm, B 420 nm, on the basis of previous studies.

A standard duodenoscope was used for side-viewing examination. Because this model of duodenoscope does not support FICE system, ampullary and periampullary evaluations were not included in the analysis. All of the endoscopic procedures were performed by two experts examiners.

"A" operator performed the exam on white light, while "B" operator used only FICE system for gastroduodenal visualization. Each EGD was divided into three phases.

During the first phase, "A" operator observed stomach and duodenum by white light recording photographic images of suspected polyps and pointing them. We intended suspected polyps on white light those larger than 1 cm and those with irregular shape or surface features.

During the second phase, "B" operator performed the exam using FICE and, like "A" operator, recorded photographic images of suspected polyps on the basis of Kudo classification<sup>[23]</sup> and capillary pattern, and pointed them.

Kudo classification classifies mucosal crypt patterns into five types, with type I and II predicting non-adenomatous lesions and type III-V predicting adenomatous lesions.

Hyperplastic polyps were suspected when the surface showed pale color with only minute thin superficial (couperose-like) vessels and round or asteroid pattern (type I and II). Adenomas were suspected in the presence of increased vascular density (darkening of the mucosal pattern or a fine meshwork of brownish/bluish vessels) and a typical tubular or gyrus-like pattern (type III-IV). Finally, type V have a non structural pattern which identifies high dysplastic or yet carcinomatous lesions.

During this phase we intended suspected those lesions with a pit pattern type III-V and those with an increased capillary density.

During the third phase, after the two endoscopists' cross-evaluation, lesions which seemed suspected only by FICE, only by white light or by both methods were resected or biopsied according to Kudo class.

Endoscopic resection was performed with diathermic loop for polyps  $\geq$  6 mm and with forceps for polyps < 6 mm. The size was estimated using on open biopsy forceps (8 mm) for comparison and recorded as smaller than 6 mm, 6 to 10 mm, 11 to 20 mm and greater than 20 mm.

The total number of FGPs was documented as below: 0 to 2 polyps, 3 to 20, 21 to 30 and more than 30 polyps. On the basis of location we identified: Fundus-corporus, antrum, duodenal bulb, II°/III° duodenal portion.

For fundic polyps seen on white light, the number of FGPs from which a biopsy specimen was taken was based on the total number of FGPs present: 3 biopsies if

3-20 polyps, 5 biopsies if 21-30 polyps, 7 biopsies if > 30 polyps<sup>[9]</sup>.

On FICE, only suspected polyps (Kudo III-V, high capillary density) were removed.

For antral and bulbar polyps, all of them were removed or biopsied both on white light than on FICE.

In the second and third duodenal portion, on white light only suspected polyps were resected or biopsied, while on FICE were biopsied those with Kudo V and those with Kudo IV and high capillary density.

Macroscopic classification of lesions followed the Paris classification<sup>[40]</sup> as polyp, superficially flat or depressed lesion, and lateral spreading tumor.

### Histology

All biopsy specimens, fixed in 10% neutral buffered formalin, were analyzed by two expert gastrointestinal pathologists blinded to size, location and number of FGPs.

In the case of multiple lesions in the same patient, each lesion was identified and placed in different flasks. Lesions were histological classified in adenomatous, hyperplastic or inflammatory polyps, fundic gland polyps, and metaplastic areas.

Adenomatous polyps were classified according to OMS classification: Tubular if holding more than 75% of tubular glands, villus if holding more than 75% of villus glands, tubulo-villus if not prevailing none of the two patterns.

Dysplasia was classified according to Vienna criteria<sup>[41]</sup> in low grade if holding nuclear enlargement, stratification and hyperchromasia with overall preservation of nuclear polarity; high grade as above but with nuclear polarity loss and glandular crowding; indefinite for dysplasia if present mild nuclear enlargement and insufficient hyperchromasia to be classified as dysplasia or if present a significant obscuring background inflammation.

The stage of duodenal polyposis was graded according to Spigelman classification modified sec. Saurin<sup>[42]</sup>, which take into account duodenal polyp number, size, histological type and grade of dysplasia. It was noted before and after FICE evaluation.

### Statistical analysis

The diagnostic performances (sensitivities, specificities, positive and negative predictive values) of FICE and WL were determined by comparing the endoscopic diagnoses with the histo-pathological findings. To identify associations of demographic, clinical and endoscopic features with the presence of FGP dysplasia or with adenomas, the Fisher exact test was used to study univariable associations of categorical demographic and endoscopic factors with the presence of dysplasia or adenomatous tissue. The Student t test was used for continuous factors. A *P* value "two tailed" < 0.05 was considered statistical significant. The strength of association was calculated by odds ratio (OR). The statistical methods of this study were reviewed by S. Milani, University of Florence.

**Table 2 Stomach and duodenum polyps**

	Patients		Patients	
Fundus	34 (49.3%)	Bulb	7 (13.5%)	
Antrum	7 (10.1%)	I <sup>o</sup> /iii <sup>o</sup> portion	35 (67.3%)	
Fundus + antrum	28 (40.6%)	Bulb+ii <sup>o</sup> /iii <sup>o</sup>	10 (19.2%)	
Total stomach	69 (100%)	Total duodenum	52 (100%)	

**Table 3 Features of fundic polyps identified by white light endoscopy**

	P1-P3	P4-P10	P11-P24	P25-P55	P56-P397
Kudo	I	II	II	II	I
Size (mm)	5	5	6-10	5	5
Paris CL	Is	Is	Is	Is	Is
Histology	HYP	IN	FGP	FGP	FGP

IN: Inflammatory; FGP: Fundic gland polyp; IP: Hyperplastic.

## RESULTS

Seventy-six consecutive FAP patients (41 male and 35 female; mean age 40.3 years old, range 24-64) underwent EGD. Among all patients, 69 (90.8%) had gastric polyps (34 only in the corpus-fundus, 7 only in the antrum and 28 in the whole stomach) and 52 (68.4%) in duodenum (7 in the bulb, 35 in second/third duodenal portion, 10 both in the bulb and the second portion of duodenum) (Table 2).

### Identification of polyps in the stomach

**Fundus:** 62 patients had a widespread fundic polyposis (81.6%); 52 of them had more than 30 fundic polyps (68.5%), 3 between 21 and 30 (3.9%) and 7 between 5 and 20 (9.2%).

On white light visualization, 397 polyps in 62 patients (6.4 polyps per patient) were removed. Three were hyperplastic polyps, 7 inflammatory while the rest were cystic fundic gland polyps. No polyp harboured dysplasia nor adenomatous foci (specificity 100%, sensitivity NV, positive predictive value NV, negative predictive value 100%, 95%CI) (Table 3).

After FICE evaluation, 10 polyps were removed from 10 patients on the basis of suspicious features of dysplasia or adenomatous tissue. All of them were cystic fundic gland polyps, none of them harboring dysplasia or adenomatous foci (specificity 97%; sensitivity NV; positive predictive value 0%; negative predictive value 100%) (Table 4).

Thirty-eight patients with fundic polyposis had also duodenal polyposis (61.2%), while among the 14 patients without fundic polyps, 10 had polyps in the duodenum (71.4%). Thus the presence of fundic polyps doesn't correlate with a higher risk to develop duodenal polyps ( $P = 0.55$ ; OR = 0.6).

**Antrum:** A total of 56 polyps were identified and

**Table 4 Features of fundic polyps identified by fujinon intelligent color enhancement**

	P1-P6	P7-P10
Kudo	III S	III L
Size (mm)	5	5
Paris CL	Is	Is
Histology	FGP	FGP

FGP: Fundic gland polyp.

**Table 5 Features of antral polyps identified by white light endoscopy**

	P1-P3	P4	P5-P10	P11-P17	P18-P24
Kudo	II	III S	III S	III S	IV
Size (mm)	6-10	6-10	5	5	5
Paris CL	II a	II a + II c	I s	I s	I s
Histology	IN	TA, LGD	TA, LGD	TA, LGD	TA, LGD
Spigelman	0	0	I <sup>o</sup>	0	0

IN: Inflammatory; TA: Tubular adenoma; LGD: Low grade dysplasia.

removed in the antrum of 35 patients (average 1.6 polyps per patient). Twenty-four polyps were identified in 35 patients by white light endoscopy (0.7 polyps per patient); 21 of them were tubular adenomas with low grade dysplasia while 3 were inflammatory polyps (specificity 88.0%; sensitivity 67.7%; positive predictive value 87.5%; negative predictive value 68.7%) (Table 5).

Beside polyps seen with conventional endoscopy, FICE was further able to identify 32 polyps in 28 patients. They were 7 tubular adenomas with low grade dysplasia, 14 inflammatory polyps, 3 areas with low grade dysplasia in the context of flogistic mucosa, 8 metaplastic areas (specificity 12.0%; sensitivity 100%; positive predictive value 58.5%; negative predictive value 100%) (Table 6).

FICE identified a higher number of polyps than traditional endoscopy (56 vs 24;  $P < 0.0001$ ), showing a better, but not statistically significant, tendency to identify adenomas and displastic areas (31 vs 21;  $P = 0.0857$ ). All but 4 polyps missed out by white light, were flat.

Eighteen of patients with antral lesions (51.4%) had polyps also in the duodenum. There is no relationship between presence of dysplasia in antral stomach and Spigelman advanced stages ( $P = 1$ ; OR = NV).

### Identification of duodenal polyps

**Bulb:** 21 polyps were seen in 17 patients (1.2 polyps per patient). All of them were endoscopically removed. White light endoscopy identified 14 polyps in 12 patients; 8 polyps were inflammatory, while 6 were tubular adenomas with low grade dysplasia (specificity 0%; sensitivity 46.2%; positive predictive value 42.9%; negative predictive value 0%) (Table 7).

During FICE evaluation, beside polyps seen with conventional endoscopy, 7 more polyps in 7 patients, five

**Table 6 Features of antral polyps identified by fujinon intelligent color enhancement**

	P25	P26	P27	P28-P30	P31	P32-P33	P34-P35	P36-P38	P39-P44	P45-P49	P50-P53	P54-P56
Kudo	V	V	III S	III L	III L	IV	IV	III L	III L	III S	III S	V
Size (mm)	5	5	5	6-10	5	5	6-10	5	5	5	6-10	5
Paris CL	II b	II a	II b	II b	II a	II b	II a	II a	II b	II b	I s	II b
Histology	IN LGD	IN LGD	IN LGD	MET	MET	MET	MET	IN	IN	IN	TA LGD	TA LGD
Spigelman	III°	II°	I°	II°	II°	0	II°	0	0	0	I°	II°

IN: Inflammatory; TA: Tubular adenoma; LGD: Low grade dysplasia; MET: Metaplasia.

**Table 7 Features of bulbal polyps identified by white light endoscopy**

	P1-P5	P6-P8	P9	P10-P12	P13	P14
Kudo	II	III S	III S	III L	IV	IV
Size (mm)	5	6-10	6-10	5	6-10	6-10
Paris CL	I s	I s	I s	II a	I s	I s
Histology	IN	TA LGD	TA LGD	IN	TA LGD	TA LGD
Spigelman	0	II°	I°	0	III°	II°

TA: Tubular adenoma; LGD: Low grade dysplasia.

**Table 8 Features of bulbal polyps identified by fujinon intelligent color enhancement**

	P15	P16-P17	P18	P19	P20-P21
Kudo	III S	IV	III S	III L	III S
Size (mm)	5	6-10	6-10	5	5
Paris CL	II a	II b	II a	II b	II b
Histology	TA LGD	TA LGD	TA LGD	TA LGD	TA LGD
Spigelman	I°	II°	II°	I°	I°

TA: Tubular adenoma; LGD: Low grade dysplasia.

of them new, were discovered. All of them were tubular adenomas with low grade dysplasia (specificity 62.5%; sensitivity 100%; positive predictive value 81.3%; negative predictive value 100%) (Table 8).

FICE was able to see further 7 polyps than traditional endoscopy, and it was able to identify a quite significant higher number of polyp in the duodenal bulb (21 vs 14;  $P = 0.069$ ). FICE added a statistical significant advantage in identifying adenomas (13 vs 6;  $P = 0.03$ ). All FICE identified polyps were flat lesions. All patients with bulbal polyps had also lesions in the gastric fundus and no adenoma in the antrum.

All patients with bulbal adenomas had polyps in the second/third portion of duodenum, while patients with inflammatory polyps had a Spigelman's stage 0.

**II°/III° duodenal portion:** Totally, 391 polyps in 45 patients (8.7 polyps per patient) were identified. Of them, 105 were removed or biopsied (26.5%). Conventional endoscopy identify 324 polyps in 45 patients (7.2 polyps per patient). Of them, 94 were removed or biopsied (2.1 polyps per patient) and they resulted: 80 tubular adenomas with low grade dysplasia, 10 inflammatory polyps and 4 tubulo-villous adenomas with low grade dysplasia. No case of high grade dysplasia (3 suspected).

(Table 9). FICE identified further 67 polyps in 35 patients and 11 were removed or biopsied in 11 subjects. All of them were tubular adenomas with low grade dysplasia. No case of high grade dysplasia (Table 10). FICE was able to identify a higher number of polyps than traditional endoscopy (8.7 vs 7.2;  $P < 0.001$ ). All polyps not seen on white light were flat lesions.

Thirty-five of patients with duodenal polyposis had also polyps in the fundus, 4 had adenomas and 2 dysplastic areas in the antrum, thus FICE didn't change any Spigelman stage just defined with conventional endoscopy.

## DISCUSSION

Duodenal adenomatous polyps are common manifestations of FAP found in 30% to 90% of patients, with a life time risk approaching 100%<sup>[5,6,43]</sup>. While rare in the general population (0.01%-0.04% of incidence at an average age of 65 years)<sup>[43]</sup>, the risk of duodenal or periampullary cancer is increased several hundreds fold in FAP patients (estimated cumulative risk of 4.5% by age 57 and a median age at presentation of 52 years)<sup>[6,8]</sup>. Duodenal cancer is the second most common cause of disease-related mortality in patients with FAP, only the

**Table 9** Features of duodenal polyps identified by white light endoscopy

	Kudo	Size (mm)	Paris CL	Histology	Spigelman
P1-P4	IV	11-20	II a	TA LGD	III°
P5-P7	V	6-10	II a	TA LGD	II°
P8-P11	IV	5	II b	TA LGD	II°
P12-P16	IIIS	6-10	II a	TVA LGD	III°
P17-P27	IIIS	5	II a	TA LGD	II°
P28-P34	IIIS	5	II a	TA LGD	I°
P35-P40	IIIS	5	II b	TA LGD	II°
P41-P43	IIIS	5	I s	TA LGD	II°
P44-P47	IIIS	5	I s	TA LGD	I°
P48-P50	IIIS	11-20	II a	TA LGD	II°
P51-P58	IIIL	5	II b	TA LGD	II°
P59-P65	IIIL	5	II a	TA LGD	II°
P66-P68	IIIL	6-10	II a	TA LGD	II°
P69-P72	IIIL	6-10	II a	TA LGD	III°
P73-P79	IIIL	6-10	II b	TA LGD	II°
P80-P84	II	5	II a	TA LGD	III°
P85-P91	IIIL	5	II b	IN	II°
P92-P94	IIIS	5	II a	IN	I°

IN: Inflammatory; TA: Tubular adenoma; LGD: Low grade dysplasia.

**Table 10** Features of duodenal polyps identified by fujinon intelligent color enhancement

	P95-P97	P98-P100	P101-P102	P103-P105
Kudo	IV	IV	V	IV
Size (mm)	5	6-10	6-10	5
Paris CL	II a	II b	II b	II b
Histology	TA LGD	TA LGD	TA LGD	TA LGD
Spigelman	I°	II°	II°	II°

TA: Tubular adenoma; LGD: Low grade dysplasia.

second to advanced and metastatic colorectal cancer. A regular and careful program of endoscopic surveillance is worthwhile in identifying early pre-malignant lesions.

Gastric polyps, particularly fundic polyps, are considered always non-neoplastic lesions, also in FAP and non-FAP patients; nonetheless high rate of their prevalence (20%-88%)<sup>[6,9-11]</sup> and several cases of dysplasia in FGPs in FAP have been recently reported, with rate of incidence up to 54%<sup>[9-11,18]</sup>.

Chromoendoscopy, both traditional and virtual, has been proven to be a good tool to increase polyps identification rate and to predict their histology<sup>[29-32]</sup>. Only one study was published on the use of FICE in the evaluation of duodenal lesions<sup>[44]</sup>. This study was conducted using a double balloon enteroscopy on patients with duodenal lesions. In this study only two FAP patients were included and FICE enhanced mucosal pattern of these polyps, and it correlated with the increase of detection of more lesions.

However, neither previous studies using traditional chromoendoscopy nor FICE, were conducted in evaluation of gastric polyps in FAP patients. To the best of our knowledge, our study is the first that has assessed the role of FICE in FGPs dysplasia identification and in the gastroduodenal polyps characterization in FAP subjects.

In agreement with the literature's data, the pre-

valence of gastric polyps was relatively elevated (90.8%), while duodenal polyps were diagnosed in 68.4% of patients, slightly lower than the reported literature value.

In the majority of FAP subjects (62/76; 83.3%), gastric polyps were so numerous that they carpeted the fundic mucosa, making difficult identifying dysplasia by random biopsies on the basis of the total number of polyps, as indicated in a recent study conducted by Bianchi *et al*<sup>[9]</sup>. Consequently, having an endoscopic technique able to target fundic biopsies is important to overcome this issue. Moreover, Bianchi *et al*<sup>[9]</sup> reported a prevalence of dysplasia in fundic polyps of 42%, while we have found only fundic gland polyps without displastic or adenomatous areas, although we have followed their sampling method. A possible explanation to this marked mismatch, could lie in the size of the polyps removed: we did find only subcentimetric polyps, while Bianchi *et al*<sup>[9]</sup> have demonstrated that the risk of dysplasia correlated with polyp size. No polyps removed had suspected superficial features according to Kudo classification, while Bianchi *et al*<sup>[9]</sup> did not adopted any classification to describe mucosal and vascular pattern; consequently we don't know if their removed polyps had or not a suspected pattern.

FICE pointed our attention on 10 fundic polyps, that seemed suspected for harboring adenomatous tissue;

however histological results did not confirmed this suspect and all of polyps resulted fundic gland polyps. In this case, FICE has not increased the identification rate of dysplasia or adenomatous tissue in fundic polyps.

Prevalence of patients with antral adenomas was about 21.1% (16/76), more than reported in the Western World data, but consistent with Japanese findings. The use of FICE could explain our result, since it has increased the identification rate of antral adenomas compared to white light, with a difference near to statistical significance ( $P = 0.0857$ ).

The very low specificity of the method (12.0%) could be explained by the presence of phlogosis (in fact almost all false positive harbored flogistic areas) able to distort the mucosal and vascular pattern, specifically enhanced by virtual chromoendoscopy.

Therefore, FICE allows to identify a greater number of adenomas to the detriment of a greater number of biopsies. Anyway this approach didn't determine a different timing in the surveillance program, but changed the attention on the antral evaluation during the following endoscopies. In duodenal bulb FICE was able to identify more adenomas than traditional endoscopy ( $P = 0.03$ ). Furthermore, all patients with FICE-identified adenomas had polyps in the duodenum too, thus the identification of bulbar adenomas didn't modify surveillance timing.

Taking into account also bulbar polyps, duodenal adenomas prevalence in FAP patients was 68.4%, with low Spigelman stages (9.2% stage III e 0% stage IV). In duodenum, FICE has allowed to see a greater number of adenomas than white light ( $P < 0.001$ ), without no modifications of Spigelman stage neither identification of high grade dysplasia.

Among FICE identified polyps, 4 lesions were suspected for high grade dysplasia, but three were inflammatory polyps at histopathological examination and one was a tubular adenoma with low grade of dysplasia. Other 7 polyps (Kudo IV) had an increased capillary density but they were tubular adenomas with low grade of dysplasia.

Finally, in duodenum, FICE increased the polyps detection rate but didn't change any Spigelman stage determined with conventional endoscopy. These data are in agreement with the little size and the absence of high grade dysplasia. Moreover this method wasn't able to modify FAP patients' prognosis, polyps' surveillance program and their therapeutic management. We did not find any relationship between the presence of gastric polyps, duodenal polyposis and high Spigelman stage ( $P = 1$ ).

Adenomas were 435 and 81 of them were diagnosed only by FICE that was able to identify a significative higher number of adenomas ( $P = 0.0062$ ). Overall, FICE has specificity, sensitivity, positive and negative predictive values higher than traditional endoscopy referring to adenomas (96.0% vs 7.1%; 98.8% vs 80.2%; 90.3% vs 44.9%; 98.8% vs 27.6%, respectively;  $P < 0.0001$ ). Conversely, it wasn't possible to correlate for high grade

dysplasia due the absence of dysplastic lesions according to the histopathological examination.

The FICE identified lesions (106/468; 22.6%) were mostly flat (67.9%;  $P = 0.029$ ) and small (all below 1 cm). According to already published data, FICE was particularly able to identify polyps with these features. It isn't clear if this ability might have clinical and procedural consequences.

In summary, in our study, FICE, like traditional endoscopy, could not identify any adenoma at risk of malignant transformation probably as a consequence of patients features (e.g., favorable genotype, recent EGD).

Nonetheless FICE significantly increases adenoma detection rate ( $P = 0.0062$ ) but does not change any Spigelman stage and thus does not modify patient's prognosis, surveillance program and treatment strategies. Probably a careful patient selection, an accurate histological examination, a concomitant use of lateral viewing endoscope, could make FICE gain that role who everybody expects in FAP patient.

## COMMENTS

### Background

Familial adenomatous polyposis (FAP) is an autosomal dominant inherited syndrome characterized by the development of colorectal cancer by the age of 40 years in nearly 100% of individuals. The use of colon endoscopic surveillance and prophylactic colectomy have strongly reduced mortality in FAP patients leading to the introduction of surveillance strategies for the prevention of other extracolonic malignancies (e.g., in the duodenum and in the stomach). Duodenal adenomatous polyps are common manifestations of FAP found in 30% to 90% of patients. Duodenal cancer is the second most common cause of disease-related mortality in patients with FAP, only the second to advanced and metastatic colorectal cancer. Gastric polyps, particularly fundic polyps, are considered always non-neoplastic lesions, also in FAP and non-FAP patients; nonetheless high rate of their prevalence (20%-88%) and several cases of dysplasia in FGPs in FAP have been recently reported, with rate of incidence up to 54%.

### Research frontiers

The observation of the pit and capillary patterns of the mucosal glands and the mucosa, respectively, by chromoendoscopy might predict the histology of mucosal lesions.

### Innovations and breakthroughs

Chromoendoscopy is a staining method that uses biocompatible dye agents which accumulate within crypt orifices during endoscopy. Chromoendoscopy has difficulty in achieving complete and even coating of the mucosal surface with the dye, requires the extra cost for the of the dye spraying equipments and extra time to perform the procedure. Fujinon Intelligent Color Enhancement (FICE™, Fujinon Corp, Saitama, Japan) is a spectral estimation technique based on arithmetically processing of a white-light image captured by a video endoscope and sent to the spectral-estimation matrix-processing circuit. Preliminary studies suggested that FICE successfully achieves enhancements of real-time observations of mucosal and microvascular patterns and may discriminate between adenomatous and non-adenomatous polyps and it may identify the presence of dysplasia. In the study, FICE, like traditional endoscopy, could not identify any adenoma at risk of malignant transformation probably as a consequence of patients features. However FICE significantly increases adenoma detection without changing patient's prognosis, surveillance program and treatment strategies. Probably a careful patient selection, an accurate histological examination, a concomitant use of lateral viewing endoscope, could make FICE gain that role who everybody expects in FAP patient.

## Applications

The timing of endoscopic and histology surveillance is currently a great challenge. Spectral estimation by Fujinon intelligent color enhancement (FICE) may identify dysplasia and discriminate between adenomatous and non-adenomatous polyps.

## Terminology

FAP is an autosomal dominant inherited syndrome who invariably develops to colorectal cancer by the age of 40 years in nearly 100% of individuals. Several endoscopic imaging techniques have been proposed to enhance the detail of these patterns. Among these, chromoendoscopy is a staining method applied in endoscopy that uses biocompatible dye agents which accumulate within crypt orifices. FICE is a modern endoscopic spectral estimation technique that successfully enhances the observation of mucosal and micro-vascular patterns.

## Peer-review

The presented results, obtained with 76 FAP patients, indicate that FICE assay offers considerable advantage over traditional chromoendoscopy to discriminate between adenomatous and non-adenomatous polyps. The authors, however, caution that the application of FICE to FAP patients while helpful in prediction the histology of the mucosal lesion and significantly increases the detection of adenomas, do not change the prognosis and treatment.

## REFERENCES

- Cruz-Correa M**, Giardiello FM. Familial adenomatous polyposis. *Gastrointest Endosc* 2003; **58**: 885-894 [PMID: 14652558 DOI: 10.1016/S0016-5107(03)02336-8]
- Heiskanen I**, Luostarinen T, Järvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. *Scand J Gastroenterol* 2000; **35**: 1284-1287 [PMID: 11199368 DOI: 10.1080/003655200453638]
- M'Koma AE**. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. *Int J Colorectal Dis* 2006; **21**: 711-720 [PMID: 16437210 DOI: 10.1007/s00384-005-0076-3]
- Nugent KP**, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. *Dis Colon Rectum* 1993; **36**: 1059-1062 [PMID: 8223060 DOI: 10.1007/BF02047300]
- Burke CA**, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. *Gastrointest Endosc* 1999; **49**: 358-364 [PMID: 10049420 DOI: 10.1016/S0016-5107(99)70013-1]
- Bülow S**, Björk J, Christensen IJ, Fausa O, Järvinen H, Moesgaard F, Vasen HF. Duodenal adenomatosis in familial adenomatous polyposis. *Gut* 2004; **53**: 381-386 [PMID: 14960520 DOI: 10.1136/gut.2003.027771]
- Björk J**, Akerbrant H, Iselius L, Bergman A, Engwall Y, Wahlström J, Martinsson T, Nordling M, Hultcrantz R. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. *Gastroenterology* 2001; **121**: 1127-1135 [PMID: 11677205 DOI: 10.1053/gast.2001.28707]
- Groves CJ**, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. *Gut* 2002; **50**: 636-641 [PMID: 11950808 DOI: 10.1136/gut.50.5.636]
- Bianchi LK**, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. *Clin Gastroenterol Hepatol* 2008; **6**: 180-185 [PMID: 18237868 DOI: 10.1016/j.cgh.2007.11.018]
- Wood LD**, Salaria SN, Cruise MW, Giardiello FM, Montgomery EA. Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms. *Am J Surg Pathol* 2014; **38**: 389-393 [PMID: 24525509 DOI: 10.1097/PAS.0000000000000146]
- Marcial MA**, Villafaña M, Hernandez-Denton J, Colon-Pagan JR. Fundic gland polyps: prevalence and clinicopathologic features. *Am J Gastroenterol* 1993; **88**: 1711-1713 [PMID: 8213712]
- Kinoshita Y**, Tojo M, Yano T, Kitajima N, Itoh T, Nishiyama K, Inatome T, Fukuzaki H, Watanabe M, Chiba T. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. *Gastrointest Endosc* 1993; **39**: 161-163 [PMID: 8388344 DOI: 10.1016/S0016-5107(93)70057-7]
- Genta RM**, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. *Clin Gastroenterol Hepatol* 2009; **7**: 849-854 [PMID: 19465154 DOI: 10.1016/j.cgh.2009.05.015]
- Wu TT**, Komacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. *Am J Surg Pathol* 1998; **22**: 293-298 [PMID: 9500770 DOI: 10.1097/0000478-199803000-00003]
- Abraham SC**, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. *Am J Pathol* 2000; **157**: 747-754 [PMID: 10980114 DOI: 10.1016/S0002-9440(10)64588-9]
- Attard TM**, Giardiello FM, Argani P, Cuffari C. Fundic gland polyposis with high-grade dysplasia in a child with attenuated familial adenomatous polyposis and familial gastric cancer. *J Pediatr Gastroenterol Nutr* 2001; **32**: 215-218 [PMID: 11321399 DOI: 10.1097/00005176-200102000-00026]
- Garrean S**, Hering J, Saied A, Jani J, Espat NJ. Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome. *Am Surg* 2008; **74**: 79-83 [PMID: 18274437]
- Jagelman DG**, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. *Lancet* 1988; **1**: 1149-1151 [PMID: 2896968 DOI: 10.1016/S0140-6736(88)91962-9]
- Park JG**, Park KJ, Ahn YO, Song IS, Choi KW, Moon HY, Choo SY, Kim JP. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. *Dis Colon Rectum* 1992; **35**: 996-998 [PMID: 1327683 DOI: 10.1007/BF02253505]
- Brosens LA**, Keller JJ, Offerhaus GJ, Goggins M, Giardiello FM. Prevention and management of duodenal polyps in familial adenomatous polyposis. *Gut* 2005; **54**: 1034-1043 [PMID: 15951555 DOI: 10.1136/gut.2004.053843]
- Park SY**, Ryu JK, Park JH, Yoon H, Kim JY, Yoon YB, Park JG, Lee SH, Kang SB, Park JW, Oh JH. Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in Korean patients with familial adenomatous polyposis. *Gut Liver* 2011; **5**: 46-51 [PMID: 21461071 DOI: 10.5009/gnl.2011.5.1.46]
- Ngamruengphong S**, Boardman LA, Heigh RI, Krishna M, Roberts ME, Riegert-Johnson DL. Gastric adenomas in familial adenomatous polyposis are common, but subtle, and have a benign course. *Hered Cancer Clin Pract* 2014; **12**: 4 [PMID: 24565534 DOI: 10.1186/1897-4287-12-4]
- Kudo S**, Hirota S, Nakajima T, Hosobe S, Kusaka H, Kobayashi T, Himori M, Yagyuu A. Colorectal tumours and pit pattern. *J Clin Pathol* 1994; **47**: 880-885 [PMID: 7962600 DOI: 10.1136/jcp.47.10.880]
- Kumagai Y**, Inoue H, Nagai K, Kawano T, Iwai T. Magnifying endoscopy, stereoscopic microscopy, and the microvascular architecture of superficial esophageal carcinoma. *Endoscopy* 2002; **34**: 369-375 [PMID: 11972267 DOI: 10.1055/s-2002-25285]
- Wanders LK**, East JE, Uitentuis SE, Leeftang MM, Dekker E. Diagnostic performance of narrowed spectrum endoscopy, autofluorescence imaging, and confocal laser endomicroscopy for optical diagnosis of colonic polyps: a meta-analysis. *Lancet Oncol* 2013; **14**: 1337-1347 [PMID: 24239209 DOI: 10.1016/S1470-2045(13)70509-6]
- Fennerty MB**. Tissue staining. *Gastrointest Endosc Clin N Am* 1994; **4**: 297-311 [PMID: 7514939]
- Pohl J**, Nguyen-Tat M, Pech O, May A, Rabenstein T, Ell C. Computed virtual chromoendoscopy for classification of small colorectal lesions: a prospective comparative study. *Am J Gastroenterol* 2008; **103**: 562-569 [PMID: 18070234 DOI: 10.1111/j.1572-0241.2007.01670.x]
- Yoshida N**, Naito Y, Inada Y, Kugai M, Inoue K, Uchiyama K,

- Handa O, Takagi T, Konishi H, Yagi N, Morimoto Y, Wakabayashi N, Yanagisawa A, Yoshikawa T. The detection of surface patterns by flexible spectral imaging color enhancement without magnification for diagnosis of colorectal polyps. *Int J Colorectal Dis* 2012; **27**: 605-611 [PMID: 22139031 DOI: 10.1007/s00384-011-1380-8]
- 29 **Kim YS**, Kim D, Chung SJ, Park MJ, Shin CS, Cho SH, Kim JS, Song IS. Differentiating small polyp histologies using real-time screening colonoscopy with Fuji Intelligent Color Enhancement. *Clin Gastroenterol Hepatol* 2011; **9**: 744-749.e1 [PMID: 21699809 DOI: 10.1016/j.cgh.2011.05.021]
- 30 **Qumseya BJ**, Wang H, Badie N, Uzomba RN, Parasa S, White DL, Wolfson H, Sharma P, Wallace MB. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review. *Clin Gastroenterol Hepatol* 2013; **11**: 1562-70.e1-2 [PMID: 23851020 DOI: 10.1016/j.cgh.2013.06.017]
- 31 **Serrano M**, Kikuste I, Dinis-Ribeiro M. Advanced endoscopic imaging for gastric cancer assessment: new insights with new optics? *Best Pract Res Clin Gastroenterol* 2014; **28**: 1079-1091 [PMID: 25439073 DOI: 10.1016/j.bpg.2014.10.002]
- 32 **Kamiński MF**, Hassan C, Bisschops R, Pohl J, Pellisé M, Dekker E, Ignjatovic-Wilson A, Hoffman A, Longcroft-Wheaton G, Heresbach D, Dumonceau JM, East JE. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2014; **46**: 435-449 [PMID: 24639382 DOI: 10.1055/s-0034-1365348]
- 33 **Picasso M**, Filiberti R, Bianchi S, Conio M. The role of chromoendoscopy in the surveillance of the duodenum of patients with familial adenomatous polyposis. *Dig Dis Sci* 2007; **52**: 1906-1909 [PMID: 17406831 DOI: 10.1007/s10620-006-9653-8]
- 34 **Lopez-Ceron M**, van den Broek FJ, Mathus-Vliegen EM, Boparai KS, van Eeden S, Fockens P, Dekker E. The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. *Gastrointest Endosc* 2013; **77**: 542-550 [PMID: 23352497 DOI: 10.1016/j.gie.2012.11.033]
- 35 **Uchiyama Y**, Imazu H, Kakutani H, Hino S, Sumiyama K, Kuramochi A, Tsukinaga S, Matsunaga K, Nakayoshi T, Goda K, Saito S, Kaise M, Kawamura M, Omar S, Tajiri H. New approach to diagnosing ampullary tumors by magnifying endoscopy combined with a narrow-band imaging system. *J Gastroenterol* 2006; **41**: 483-490 [PMID: 16799891 DOI: 10.1007/s00535-006-1800-7]
- 36 **Jung SW**, Lim KS, Lim JU, Jeon JW, Shin HP, Kim SH, Lee EK, Park JJ, Cha JM, Joo KR, Lee JI. Flexible spectral imaging color enhancement (FICE) is useful to discriminate among non-neoplastic lesion, adenoma, and cancer of stomach. *Dig Dis Sci* 2011; **56**: 2879-2886 [PMID: 21800158 DOI: 10.1007/s10620-011-1831-7]
- 37 **Kikuste I**, Marques-Pereira R, Monteiro-Soares M, Pimentel-Nunes P, Areia M, Leja M, Dinis-Ribeiro M. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. *Scand J Gastroenterol* 2013; **48**: 1108-1117 [PMID: 24047392 DOI: 10.3109/00365521.2013.825315]
- 38 **Pittayanon R**, Rerknimitr R, Wisedopas N, Ridditid W, Kongkam P, Treeprasertsuk S, Angsuwatcharakon P, Mahachai V, Kullavanijaya P. Flexible spectral imaging color enhancement plus probe-based confocal laser endomicroscopy for gastric intestinal metaplasia detection. *J Gastroenterol Hepatol* 2013; **28**: 1004-1009 [PMID: 23432088 DOI: 10.1111/jgh.12185]
- 39 **Kikuste I**, Stirna D, Liepniece-Karele I, Leja M, Dinis-Ribeiro M. The accuracy of flexible spectral imaging colour enhancement for the diagnosis of gastric intestinal metaplasia: do we still need histology to select individuals at risk for adenocarcinoma? *Eur J Gastroenterol Hepatol* 2014; **26**: 704-709 [PMID: 24901816 DOI: 10.1097/MEG.0000000000000108]
- 40 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. *Gastrointest Endosc* 2003; **58**: S3-43 [PMID: 14652541 DOI: 10.1016/S0016-5107(03)02159-X]
- 41 **Schlemper RJ**, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfing M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. *Gut* 2000; **47**: 251-255 [PMID: 10896917 DOI: 10.1136/gut.47.2.251]
- 42 **Spigelman AD**, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. *Lancet* 1989; **2**: 783-785 [PMID: 2571019 DOI: 10.1016/S0140-6736(89)90840-4]
- 43 **Adedeji OA**, Trescoli-Serrano C, Garcia-Zarco M. Primary duodenal carcinoma. *Postgrad Med J* 1995; **71**: 354-358 [PMID: 7644397 DOI: 10.1136/pgmj.71.836.354]
- 44 **Neumann H**, Fry LC, Bellutti M, Malfrather P, Mönkemüller K. Double-balloon enteroscopy-assisted virtual chromoendoscopy for small-bowel disorders: a case series. *Endoscopy* 2009; **41**: 468-471 [PMID: 19418402 DOI: 10.1055/s-0029-1214603]

**P- Reviewer:** Caboclo JLF, Slomiany BL **S- Editor:** Kong JX

**L- Editor:** A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**  
8226 Regency Drive, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

